Core Points - Microbix Biosystems Inc. has signed a Memorandum of Understanding (MOU) with the Australian Centre for the Prevention of Cervical Cancer (ACPCC) to supply PROCEEDx™FLOQ Quality Assessment Products (QAPs) for HPV testing [1][2] - The partnership aims to enhance the quality management of testing for high-risk HPV infections, which are responsible for most cervical cancer cases [1][4] - The EPICC program, supported by the Australian Government, aims to eliminate cervical cancer in the Indo-Pacific region through improved prevention, diagnosis, and treatment [2][8] Company Overview - Microbix Biosystems Inc. is a life sciences innovator with over 120 employees, targeting sales of C$ 2.0 million or more per month [5] - The company specializes in manufacturing and exporting critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory QAPs [5][6] - Microbix's products are available in over 30 countries and are supported by a network of international distributors, with various accreditations including ISO 9001 & 13485 [5][6] Industry Context - The EPICC program is a humanitarian initiative that has already shown success in countries like Malaysia and Papua New Guinea, and is now expanding to include 12 Indo-Pacific nations [3] - The ACPCC has been operating for 60 years, focusing on preventing cervical cancer through vaccination and screening programs [7] - The EPICC consortium includes leading Australian cancer research partners and aims to advance national cervical cancer elimination strategies in collaboration with Ministries of Health in the region [8]
Microbix & ACPCC support efforts to eliminate cervical cancer in the Indo-Pacific